PF614-MPAR is under clinical development by Ensysce Biosciences and currently in Phase I for Substance (Drug) Abuse. According to GlobalData, Phase I drugs for Substance (Drug) Abuse have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PF614-MPAR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ensysce Biosciences overview
Ensysce Biosciences is a biotechnology company. It offers proprietary abuse-resistant opioid prodrug technology. The company’s pipeline products include PF614- TAAP oxycodone for pain, respiratory diseases, PF8001 / PF8026- TAAP amphetamine to deter prescription drug abuse at the molecular leveln, OUD is to abuse deterrent technology for Opioid Use Disorder. The company offers services such as clinical programs, preclinical programs, TAAP technology, pain medications, drug delivery, MPAR technology, proprietary prodrug technology, abuse resistant technology among others. It provides its products and services to healthcare, medical and pharmaceutical sectors. Ensysce Biosciences is headquartered in San Diego, California, the US.
For a complete picture of PF614-MPAR’s drug-specific PTSR and LoA scores, buy the report here.